Israel Gasperin Presents Zentrela at LSI USA ‘23

Transcription

Hello everyone, my name is Israel Gasperin. I am the founder and CEO of Zentrela. We are a Canadian neuro technology company that has developed a novel EEG test for objectively quantifying the effects drugs, half of the brain. And the reason why we've developed this technology is because there is an unmet global need for objective and measurable drug effect data. For example, in the law enforcement market, if you think about it, law enforcers, or the police has never had an objective way of detecting or confirming if a person needs alcohol or drug impaired, and if so how impaired a person is. And in fact, that's why the Ontario government granted us $1.2 million to develop this technology in order to the tech cannabis impaired driving during the legalization of cannabis in Canada, between 2016 and 2019. But also during that time, we found another immediate and larger market needs for the producers of legal cannabis products in order to reliably validate the efficacy of their products to create the intended effects. Today, they don't have an objective way of validating if they create efficiently the effects that they were intended or created for. So as a result of that they are investing millions of dollars every year in developing and commercializing products that at the end perform poorly. And that's why the industry is in a in a crisis today. I'll get back to this commercial application in a second. But before that, I would like to create awareness why this problem exists and why this global needs has never been added before, which is very straightforward. body fluid test. They only measure concentration levels of a substance like in saliva, urine, blood or breath. But they can't tell you if a person is experiencing psychoactive therapeutic or mood effects, then you have subjective tests that are biased. And that's why they have never been adopted by the market so that I just kind of share share with you. And finally, EEG technology has been used for decades to study drug effects on the brain. But the problem is that this analysis has been manual is low, costly, non standardized and non measurable. Therefore EEG has never been a scalable or valuable for all the markets that need objective cannabis or drug effect data. So our solution is to create artificial intelligence. We are training AI models that are analyzing EEG data in a standardized, objective and more accurate way that if we were doing it manually or ourselves, so in order to make this approach work since 2016, we have been conducting controlled trials at a scale that have allowed us to build the world's largest database of EEG recordings, more than 20,000 tests that are accurately labeled with scientifically characterize mental states like being cannabis intoxicated, for example. And as a result, we have trained an AI model that has become the standard the most objective and accurate way in detecting if a person is cannabis impaired or not on their fully blinded in an uncontrolled scenarios. We have two peer reviewed papers and an independent study that proves these unprecedented accuracy. And I'll show you these papers in a second. But the second novel component of our eg tests that I would like to bring to your attention is our proprietary method for quantifying the strength of the of a drug effect. And basically this method consists of administering an egotist recording two minutes of EEG data segmenting the data. And then AI models are analyzing the data, the total number of segments or in other words, the total amount of time that your brain activity or your EEG is alter or associated with that drug effect is allowing us to quantify how strong is being the experience of that effect at certain time. And when you use it under control the scenarios, licensed cannabis producers for the first time ever are able to objectively and accurately characterize the psychoactive effects that their products create. And when they do this type of research at the r&d stage, they are able to effectively and reliably validate the efficacy of new formulations and warranty that succeeds when they invest in launching them to the market or when they do this type of product defect testing, when with commercially available products, they are able to identify those that perform poorly, so they can discontinue or reformulate them, and in that way safe in operating expenses, or vice versa. If these results show that their products are performing general in an effective way, they are leveraging this type of objective and factual data in order to launch trustworthy and regulatory compliant consumer education campaigns that is changing the way they position and market the products and in that way, you know, succeed in their business, which is driving more product sales. As I mentioned, we have scientifically validated that we're AI driven approach for analyzing EEG data and quantifying drug effects. In this case with the first AI model. These two peer reviewed papers are publicly available in different neuroscience journals, I bet you can take a look at them they are available. In terms of traction, we have raised $2.2 million from the Ontario government funds and angel investment with one single model, we are already in the market generating revenue, working with the largest producers in North America. And the way we are generating profit or making monetizing our data is by licensing need multiple times for different purposes, r&d, or marketing.Now, the last piece that I want to bring to your attention, guys, is the disruption that our technology is going to create by having the unique ability of objectively quantify in mental states. And in that way, we can measure how any type of substance or wellness or therapeutic or medical solutions are going to create a positive effect on any of those mental states. So they can objectively measure and demonstrate how effective their solutions are to help people with their well being. And the way we are going to scale up and you know address the global demand for objective drug effect data is just to simply replicate the LabCorp business model. We will continue equipping our clients with low cost portable EEG devices that are fully proprietary so they can do the wrong type of investigations, testing clinical trials or controlled trials in order to change the way they manufacture drugs or they prevent the consumption of drugs and driving under the influence of cannabis. We are raising serious save funds and we are looking for a strategic investors that also believe in this vision and finding another as exciting as we find it in order to make it a reality. So if anyone here is interested to learn more about my company and my team and the technology, I will be happy to talk to you off the stage. And that's it. Thank you very much for your time.